Bristol-Myers Squibb’s (BMY) virology portfolio includes products for the treatment of chronic virus infections like Hepatitis B virus infections, Hepatitis C virus (or HCV) infections, and HIV infections.
The above chart shows revenues for the Hepatitis C franchise as well as other virology products over the last few quarters.
Hepatitis B franchise
The Hepatitis B franchise includes Baraclude, an oral antiviral for the treatment of Hepatitis B infections. Baraclude revenues fell 9% to $273 million in 2Q17, compared to $299 million in 2Q16, driven by lower sales due to generic competition from Teva Pharmaceuticals’ (TEVA) entecavir tablets.
Hepatitis C franchise
Hepatitis C franchise includes the two drugs: Daklinza and Sunvepra.
Daklinza is a drug used in combination with sofosbuvir, with or without ribavirin, for the treatment of chronic hepatitis C virus infections of Genotype 1 or Genotype 3.
Sunvepra is used for the treatment of chronic hepatitis C virus infections of Genotype 1.
The combined revenues for these drugs fell ~79% to $112 million in 2Q17, compared to $546 million in 2Q16, mainly due to competition in international markets.
The HIV franchise includes two drugs—Reyataz and Sustiva. These drugs are used in combination with other antivirals for the treatment of HIV-1 infections.
Reyataz reported revenues of $188 million in 2Q17, a 24% fall from the $247 million in 2Q16, due to lower sales following competition from other HIV drugs.
Sustiva reported revenues of $188 million in 2Q17, a 31% fall from revenues of $271 in 2Q16, due to lower sales following the loss of exclusivity and competition from other drugs.
To divest company-specific risks, investors can consider ETFs like the VanEck Vectors Pharmaceutical ETF (PPH), which invests 5.1% of its total assets in Bristol-Myers Squibb (BMY). PPH also invests 8.9% of its total assets in Johnson & Johnson (JNJ), 5.0% in Sanofi (SNY), and 4.7% in AstraZeneca (AZN).